Comparison for Use of Telmisartan and Candesartan on 3-Year Clinical Outcomes After Acute Myocardial Infarction in Korean Population: From the Korea Acute Myocardial Infarction Registry-National Institutes of Health

초록

Background This study was to investigate a comparison for use of Telmisartan and Candesartan on 3-year clinical outcomes in acute myocardial infarction (AMI) patients who underwent successful percutaneous coronary intervention with drug-eluting stent. Methods The study population was enrolled from the Korea AMI registry (KAMIR)-National Institutes of Health (NIH). A total of 13,104 AMI patients were enrolled from November 2011 to December 2015. The key combined primary endpoint was major adverse cardiac events (MACE), the composite of total death, MI, and revascularization. The key secondary endpoints were the occurrence of any clinical events such as total death, MI, revascularization, stroke, and re-hospitalization due to heart failure. The key endpoints up to 3-year were evaluated. To adjust baseline potential confounders, a propensity score matching (PSM) analysis was performed. Results After PSM analysis, two matched groups (500 pairs) were generated and their baseline patient- and procedure-related characteristics were well balanced. During 3-year clinical follow up, there were no differences in the incidence of key combined primary and secondary endpoints between the two groups. Conclusion The use of Telmisartan showed similar clinical results up to 3 years as compared with Candesartan use in Korean AMI patients.